Jade: Differentiated IgAN Profile and Multi-Asset Upside Make $2B Peak Sales for JADE101 Look Conservative

Matt Phipps, an analyst from William Blair, has initiated a new Buy rating on Jade Biosciences (JBIO).

Matt Phipps has given his Buy rating due to a combination of factors, primarily the belief that Jade’s lead asset JADE101 can deliver a clearly superior clinical profile versus earlier IgA nephropathy entrants. He expects healthy volunteer data to confirm meaningful IgA reduction at a convenient, infrequent autoinjector dose, which he views as a strong signal for future kidney outcomes and long-term treatment durability in IgAN.

At the same time, he sees notable weaknesses in competing APRIL-targeting drugs, including immune responses, infection concerns, and higher injection burden, creating room for a differentiated, later-arriving therapy to gain substantial share. He also highlights management’s disease-area expertise and the additional upside from JADE201, a BAFF-R antibody with multi-indication potential, supporting his view that JADE101’s projected $2.0 billion peak sales may ultimately prove conservative.

According to TipRanks, Phipps is a 4-star analyst with an average return of 4.6% and a 44.27% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Evommune, Inc., Argenx Se, and Incyte.

In another report released on March 7, LifeSci Capital also initiated coverage with a Buy rating on the stock with a $24.00 price target.